---
title: Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
nct_id: NCT05099549
overall_status: TERMINATED
phase: PHASE1, PHASE2
sponsor: NKGen Biotech, Inc.
study_type: INTERVENTIONAL
primary_condition: Squamous Cell Carcinoma of Head and Neck
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05099549.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05099549"
ct_last_update_post_date: 2024-03-01
last_seen_at: "2026-05-12T07:30:41.914Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

**Official Title:** A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

**NCT ID:** [NCT05099549](https://clinicaltrials.gov/study/NCT05099549)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 11
- **Lead Sponsor:** NKGen Biotech, Inc.
- **Collaborators:** Affimed GmbH
- **Conditions:** Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
- **Start Date:** 2021-11-03
- **Completion Date:** 2023-09-21
- **CT.gov Last Update:** 2024-03-01

## Brief Summary

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

## Detailed Description

The study will be conducted in two phases. The Phase 1/dose escalation phase will gather preliminary safety and tolerability data for escalating doses of AFM24 in combination with SNK01 at a fixed dose in order to determine the MTD/RP2D for the combination dose regimen to be used in the Phase 2a/expansion.

The Phase 2a/expansion portion of the study will gather additional safety, tolerability, efficacy, and anti-tumor activity information for the combination of AFM24 with SNK01 in subjects with three types of advanced or metastatic EGFR-expressing cancers.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Key Inclusion Criteria:

1. Capable of giving signed informed consent
2. Males and females age ≥ 18 years
3. Phase 1/Dose Escalation : any histologically confirmed advanced or metastatic EGFR-positive malignancy for which all standard of care treatment options have been received and are no longer effective or are considered inappropriate at the discretion of the investigator.
4. Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort).
5. Additional Criteria for Phase 2a/Expansion: subjects must have a disease history specific to their disease as listed below:

   1. EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair proficient. Subjects must have received ≥ 1 lines of previous combination therapy and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF targeting agent and, if considered appropriate by the treating physician, an EGFR targeted antibody.
   2. EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease, which must have included platinum-based therapy, fluoropyrimidine, and an anti PD 1/PD-L1 antibody.
   3. EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR WT) whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease. Subjects must have received at least a platinum-based doublet in combination with anti-PD1/PD-L1 antibody or must have received a platinum-based doublet followed by an anti-PD1/PD-L1 antibody.
6. One or more measurable tumors lesions per RECIST v1.1
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
8. Adequate bone marrow, hepatic and renal function.

Key Exclusion Criteria:

1. Superior vena cava syndrome contra-indicating hydration
2. Untreated or symptomatic central nervous system (CNS) metastases
3. No resolution of specific toxicities related to any prior anti-cancer therapy to Grade ≤ 1 according to the NCI-CTCAE v.5.0 (except peripheral or motor neuropathy, lymphopenia and alopecia)
4. Treatment with systemic anticancer therapy or an investigational device within 4 weeks (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent (if half-life is known and it is shorter) before the first dose of study treatment.
5. Radiation therapy within 2 weeks before first dose of any study treatment or unresolved (NCI CTCAE v5.0 Grade \> 1) toxicity from previous radiotherapy
6. Clinically significant cardiovascular disease
7. Major surgery within 4 weeks prior to any study treatment administration
8. Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol
9. Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy within 14 days prior to first dose of study treatment.
10. Known history of testing positive for human immunodeficiency virus (HIV), and/or positive test for Hepatitis B virus surface antigen (HBsAg) and/or positive Hep C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.
11. Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring systemic immunosuppressive therapy
12. A serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
13. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study
```

## Arms

- **Phase 1, Dose Escalation** (EXPERIMENTAL) — It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.

SNK01 (fixed dose) will be administered weekly by IV infusion.
- **Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)** (EXPERIMENTAL) — SNK01 (fixed dose) will be administered weekly by IV infusion.
- **Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)** (EXPERIMENTAL) — SNK01 (fixed dose) will be administered weekly by IV infusion.
- **Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)** (EXPERIMENTAL) — SNK01 (fixed dose) will be administered weekly by IV infusion.

## Interventions

- **AFM24** (DRUG) — Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
- **SNK01** (BIOLOGICAL) — Patient-specific ex-vivo expanded autologous natural killer cells.

## Primary Outcomes

- **Phase 1/Dose Escalation** _(time frame: 28 days starting on cycle 1 day 1)_ — Determine the maximum tolerated dose (MTD) of AFM24 in combination with SNK01. To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.
- **Phase 1/Dose Escalation** _(time frame: 28 days starting on cycle 1 day 1)_ — Determine the recommended phase 2 dose (RP2D) of AFM24 in combination with SNK01.

To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_ — Determine objective response rate (ORR) of AFM24 in combination with SNK01. Determine ORR using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1

## Secondary Outcomes

- **Phase 1/Dose Escalation** _(time frame: Up to 24 months)_
- **Phase 1/Dose Escalation** _(time frame: Up to 24 months)_
- **Phase 1/Dose Escalation** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 1/Dose Escalation** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 1/Dose Escalation** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 1/Dose Escalation** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 1/Dose Escalation** _(time frame: Up to 24 months)_
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_
- **Phase 2a/Expansion** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 2a/Expansion** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 2a/Expansion** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 2a/Expansion** _(time frame: 28 days starting on cycle 1 day 1)_
- **Phase 2a/Expansion** _(time frame: Up to 24 months)_

## Locations (3)

- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- University of Chicago, Chicago, Illinois, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.usc/norris comprehensive cancer center|los angeles|california|united states` — added _(2026-05-12)_
- `locations.sarcoma oncology center|santa monica|california|united states` — added _(2026-05-12)_
- `locations.university of chicago|chicago|illinois|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05099549.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05099549*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*